Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page i CLIN ICAL STUDY PROTOCOL 
Title: A Post-Market, Prospective, Multicenter, Singl e-Arm Trial 
of XenMatrix™ AB Su rgical Graft in All CDC Wound 
Class Ventral or  Incisional Midline Hernias 
Protocol Number: DVL-HE-012 
Study T ype: Post-Market 
Date: August 7, 2018  
Version:  3.0 
Study Device: Bard
 XenMatrix™ AB Surgical Graft 
Sponso r: Davol In c. 
Subs idiary of C. R. Bard, In c. 
100 Crossings Boul evard 
Warwick, RI 02886  
Phone: 1-800-556-6756  
Sponsor  Cont acts: Dawn Heimer, PhD 
Davol In c. 
100 Crossings Boul evard 
Warwick, RI 02886  
Telephon e: 401-825-8681  
E-mail: dawn.heimer@crbard.com
NCT number: [STUDY_ID_REMOVED]
NCT number added post approval as per CT.gov requirement.
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page ii  
  
 
Protocol Signa ture Page 
 
The Investigator agrees to condu ct the clinical study which is the  subject of this p rotocol in 
accordance with the  Clini cal Study Agreement, this protocol, all applicable laws and 
regulations, and the  conditions of  approval impos ed by the reviewing Institution al Review 
Board. 
 
 
 
Agreed to by (Investigator): 
 
 
 
 
Printed Na me – Investigator 
 
 
 
 
Signature  – Investigator 
 
 
 
 
Date 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 3  
  
 
Protocol Abbreviations/ Acronyms 
Abbreviation/Acronym  Definition 
ADL Activiti es of Daily Living 
AE(s) Adverse Event(s) 
AMP Antimi crobial Prophylaxis 
ASA American Society of Anesthesiolo gy 
Bard C. R. Bard, Inc. 
BMI Body Mass Index 
CDC Centers for Disease Control 
C. di fficile Clost ridium di fficile bacterium 
CFR Code  of Federal Regulations 
cm Centimeter 
COPD Chronic Obstructive Pulmon ary Disease 
CST Compon ent Separation Technique  
CT Comput ed Tomography 
CV Curriculum Vitae 
E. aerogenes Enterobacter aerogenes bacterium 
E. Coli  Escherichia coli bacterium 
eCRF(s) Electronic Case Report Form(s) 
e.g. For example  
etc. Et cetera, and oth ers 
F Fahrenheit 
FDA Food and Drug Administ ration 
HIPAA Health Insurance Portability and Accountability Act 
HIV Human Immunod eficiency Virus 
ICF Informed Cons ent Form 
i.e. Id est, th at is 
IFU Instructions for Use 
Inc. Incorporated 
IRB Institution al Review Board 
ITT Intent-to-Treat 
kg Kilogram 
LTFU Loss/Lost to Follow-up 
m Meter 
mg / dL Milli grams p er deciliter 
mITT Modi fied Intent-to-Treat 
MRI Magnetic Resonance Imaging 
MRSA  Methicillin-resistant Staphylococcus aureus 
N Number 
POD Post-operative Day 
SAE(s) Serious Adverse Event(s) 
SAP Statistical Analysis Pl an 
SCIP Surgical Care Improvement Project 
SF-12 Short-Form-12 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 4  
  
 
TAR  Transversus Abdominis  Release 
U.S. United States 
USDA United States Department of Agriculture 
V.A.C.® Vacuum-Assisted Closu re 
XenMatrix™ AB XenMatrix™ AB Surgical Graft (device) or surgical graft 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 5  
  
 
TABLE OF  CONTENTS 
1. INTRODUC TION  ................................ ................................ ................................ ...........  1 
1.1. Background  ................................ ................................ ................................ ..... 1 
1.2. Rationale  ................................ ................................ ................................ .........  3 
1.3. Device Description  ................................ ................................ ..........................  4 
2. STUDY OBJE CTIVES ................................ ................................ ................................ ... 4 
3. STUDY ENDPOINTS ................................ ................................ ................................ ..... 4 
3.1. Primary Endpoint  ................................ ................................ ..........................  4 
3.2. Seconda ry Endp oints  ................................ ................................ .....................  4 
4. STUDY DESIGN ................................ ................................ ................................ .............  5 
5. STUDY POPULATION ................................ ................................ ................................ . 5 
5.1. Number Of Subjects  ................................ ................................ .......................  5 
5.2. Eligib ility Criteria  ................................ ................................ ..........................  5 
5.2.1.  Inclusion C riteria  ................................ ................................ ................  5 
5.2.2.  Exclusion C riteria  ................................ ................................ ...............  5 
6. STUDY PROCEDURES ................................ ................................ ................................ . 6 
6.1. Subject Screening And Bas eline Evaluation  ................................ ................  6 
6.1.1.  Informed Cons ent  ................................ ................................ ...............  7 
6.1.2.  Enrollment  ................................ ................................ ..........................  7 
6.1.3.  Eligibility  ................................ ................................ ............................  7 
6.1.4.  Assignment of Subject Number  ................................ ..........................  7 
6.1.5.  Demographics And Medical History  ................................ ..................  8 
6.1.6.  Physical Examination  ................................ ................................ .........  8 
6.1.7.  Quality of Life Assessment  ................................ ................................  8 
6.2. Index Procedure  ................................ ................................ .............................  8 
6.2.1.  Perioperative Care  ................................ ................................ ..............  8 
6.2.2.  Abdomin al Wall Reconstruction/Ventral or Incision al Hernia Surgery 
……………………………………………………………………….9  
6.2.3.  Immediate Postop erative Care...........................................................  10 
6.2.4.  Surgical Details  ................................ ................................ ................  10 
6.3. Subject Follow-up  ................................ ................................ .........................  10 
6.3.1.  Assessments  ................................ ................................ ......................  11 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 6  
 6.3.2.  Unscheduled Visits  ................................ ................................ ...........  11 
6.4. Time And Ev ents Schedule  ................................ ................................ ..........  13 
6.5. Subject Discontinua tion  ................................ ................................ ...............  14 
6.6. Replacement of Subjects  ................................ ................................ ..............  14 
7. ADV ERSE E VENTS  ................................ ................................ ................................ .... 14 
7.1. Definition of Events  ................................ ................................ ......................  14 
7.2. Definition of Serious Adverse Events (SAE)  ................................ ..............  15 
7.3. Relationship Of Adverse Event To Device/Procedure  ..............................  15 
7.4. Severity of Adverse Events  ................................ ................................ ..........  15 
7.5. Reporting Of  Events  ................................ ................................ .....................  16 
8. MECHANICAL FAILURES, MALFUNCTIONS AND DEFECTS  .......................  16 
9. RISK/BENEFIT ANA LYSIS  ................................ ................................ ......................  17 
10. CASE REPORT FORMS  ................................ ................................ ............................  17 
11. STATISTICAL METHODS  ................................ ................................ ........................  17 
11.1. Study Hypo thesis  ................................ ................................ ..........................  17 
11.2. Sample Size Consid erations  ................................ ................................ .........  18 
11.3. Data Analysis  ................................ ................................ ................................  18 
11.3.1.  Analysis Popul ation  ................................ ................................ ..........  18 
11.3.2.  Primary Endpoint  ................................ ................................ ..............  18 
11.3.3.  Secondary Endpoints  ................................ ................................ ........  18 
11.4. Data Analysis Consid erations  ................................ ................................ ...... 19 
11.4.1.  Data pooling  ................................ ................................ ......................  19 
11.4.2.  Handling  of missing  data  ................................ ................................ .. 19 
11.5. Interim Analysis  ................................ ................................ ............................  19 
12. ADM INISTRATIVE REQUIREMENTS  ................................ ................................ .. 19 
12.1. Investigator Selection  ................................ ................................ ...................  19 
12.2. Regulatory and E thical Consid erations  ................................ ......................  20 
12.2.1.  Institution al Review Board (IRB) Approval  ................................ ..... 20 
12.2.2.  Informed Cons ent and HIPAA Authorization  ................................ .. 20 
12.3. Protocol Adherence And Deviations  ................................ ...........................  21 
12.4. Device Accountabili ty  ................................ ................................ ...................  21 
12.5. Data Collection  ................................ ................................ ..............................  21 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 7  
 12.6. Subject Compensation  ................................ ................................ ..................  21 
12.7. Communications Wi th The  Sponsor  ................................ ...........................  21 
12.8. Required Documentation  ................................ ................................ .............  22 
12.9. Publications  ................................ ................................ ................................ ... 22 
13. SITE MONITORING ................................ ................................ ................................ . 22 
13.1. Study I nitiation Visit  ................................ ................................ ....................  23 
13.2. Ongoing Monitoring Visits  ................................ ................................ ..........  23 
13.3. Final Monitoring Visit  ................................ ................................ ..................  23 
14. TERMINATION  OF STUDY  ................................ ................................ .....................  23 
15. REPORTING REQUIREMENTS ................................ ................................ .............  24 
16. RECORD RETE NTION ................................ ................................ .............................  24 
17. REFERENCES ................................ ................................ ................................ ............  25 
18. APPENDICES ................................ ................................ ................................ ..............  30 
18.1. Principal Inv estigator Information  ................................ .............................  31 
18.2. Routine Culture  ................................ ................................ ............................  32 
18.3. Surgical Site Infection Classification  ................................ ..........................  34 
18.4. Clavien Dindo Classification  ................................ ................................ ........  37 
18.5. Instructions for Use  ................................ ................................ ......................  38 
List of Tables and Figures 
Table 1: Center for Disease Cont rol’s Surgical Wound Cl assification System .......................  2 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 1 of 42  
  
 
 
1. INTRODUC TION  
 
 
1.1. Background  
 
With mo re than 2 million  abdomin al operations p erformed annually in the  United 
States (U.S.) and with up  to 20%  of those  patients developing  ventral or incision al 
hernias, abdomin al wall defec ts and in cision al hernias represent a challenging 
surgical condition. [1, 2]  Approximately 348,000  ventral hernia repairs are 
performed on a yearly basis. [3] There are several options for repair, including 
primary repair, synthetic or biolo gic material placement, repair with relaxing 
incisions, and use  of musculofascial flaps, utili zing both op en and laparoscopic 
approaches. [2] However, there is no clear-cut consensus regarding the optimal 
hernia repair techniqu e, particularly where patient co-morbiditi es exist and a high 
risk of  infection is p resent. 
 
Simple  suture repair has been associated with a high risk of  hernia recurrence, with 
reports ranging from 1 0% to 55%  recurrence rate. [4-7]   Primary suture repair has 
been nearly abandoned for the repair of hernias which are greater than five 
centimeters (cm) in size. [4-7] As a result, m any ventral hernia repair procedures 
involve  the use of a mesh material. 
 
Synthetic mesh repair procedures, either open or laparoscopic, have been reported to 
lead to fewer recurrences compared to p rimary repairs. [8-11] Improved outcomes 
with m esh are believed to be related to better distribution of  tension on the  fascial 
edges and sutu res when mesh is us ed in h ernia repair procedures. [41] However, 
compl ex cases and large abdomin al wall defects continue  to pose  a challenge to 
surgeons. [32] Factors such as patient co-morbiditi es, defect size, location, tissue 
viability and degree of contamination are included in a surgeon’s assessment and 
decision -making process. [12, 30]  These large abdomin al wall defec ts have been 
associated with recurrence rates of up to 4 6%. [13] 
 
Today many surgeons prefer to close large defects primarily and th en reinforce the 
primary repair with biolo gic or synthetic mesh.  In order to close these large defects 
surgeons rely on one  of several compon ent release techniqu es.  One approach to 
addressing the compl exity of large abdomin al wall defec t (>5 cm in width)  repair is 
the Compon ent Separation Method.  The method was developed by Ramirez et al. in 
1990 and was based on the  assumption th at separating the muscle compo nents of  the 
abdomin al wall would allow mobili zation of  the entire abdomin al wall as a compl ete 
unit, allowing the surgeon to b ring the midline  together with less tension, thus 
allowing better repair of large abdomin al wall defects. [14]  Numerous v ariations on 
the original compon ent separation m ethod h ave emerged and have reported 
recurrence rates from 0%  to 30 %.[14-19]  These variations range from procedural 
techniqu e, selection and use of prosthetic repair material, and lo cation of  placement 
of such material.  Prelimin ary results s uggest minim ally invasive techniqu es may be 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 2 of 42  
  
 
associated with fewer complications; ho wever, there are simil ar recurrence rates 
between laparoscopic and open repair. [4, 20, 35]  
 
Althou gh positive  outcomes have been reported with the  compon ent separation 
technique  when used with synthetic mesh, the  presence of a permanent foreign body 
material may be associated with persistent wound  infection, fistula  formation, 
seroma developm ent, m esh contraction and m igration, vis ceral erosions, adhesions, 
chronic pain and foreign body reactions. [29] 
 
The reported risk of  a wound in fection following ventral hernia repair ranges 
between 0%  and 23 %. [11, 21 -28]  Deep mesh in fection frequently results in m ajor 
compli cations in cludin g, the need for repeat surgery with or  without m esh removal, 
wound d ehiscence, prolonged recovery, decreased patient qu ality of life, and 
extended lon g-term hospit alization. [29] 
 
Biologic grafts provide a temporary collagen scaffold which is remodeled and 
replaced with the  body’s own tissue  over time to repair a hernia defect with fewer 
postop erative chronic wound compli cations. [33-35] These grafts aim to address 
many of the deficiencies of synthetic mesh, su ch as the need for addition al surgery to 
remove  infected permanent mesh in the  event of surgical site infection while 
preserving the positive  attributes of strength and the potential for durable, definitive 
hernia repair. [8, 36, 39]  
 
Risk of  surgical site  infection h as been defined and categorized in the  Centers for 
Disease Cont rol’s (CDC) Guidelines for the prevention of  surgical site  infection 
publish ed in 1999 (see Table 1). [49] This classification system has provided 
conformity in the  definitions us ed to classify and categorize general surgical site 
infections (see Table 1). 
 
 
 
Table  1: Center for Disease Cont rol’s Surgical Wound Cl assification System 
 
Class CDC Surgical Wound  Classification49 
 
 
 
I Clean: An unin fected operative wound in which no inflammation is  
encountered and the  respiratory, alimentary, genital, or uninfected urinary tract 
are not entered. In addition, clean wounds  are primarily closed and, if 
necessary, drained with closed drainage. Operative incision al wounds th at 
follow  nonp enetrating (blunt) trauma should be  included in this category if they 
meet the criteria. 
 
 
 
II Clean-Cont aminated: An operative wound in which the  respiratory, alimentary, 
genital, or urinary tracts are entered under controlled conditions and without 
unusu al contamination. Sp ecifically, operations involving  the biliary tract, 
appendix, vagina, and oropharynx are included in this category, provided no 
evidence of infection or  major break in t echnique  is encountered. 
 
III Cont aminated: Open, fresh, accidental wounds.  In addition, op erations with 
major breaks in st erile technique  (e.g., open cardiac massage) or gross spill age 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 3 of 42  
  
 
 
Class CDC Surgical Wound  Classification49 
 from the  gastrointestinal tract, and in cisions in which acute, nonpu rulent 
inflammation is encountered including  necrotic tissue  without evidence of 
purulent drainage (e.g. dry gangrene) are included in this category. 
 
 
IV Dirty-Infected: Old traumatic wounds with retained devitalized tissue  and those  
that involve  existing  clinical infection or  perforated vis cera. This d efinition 
suggests th at the organisms causing  postop erative infection were present in the 
operative field before the operation. 
 
 
The ability of biologic grafts to suppo rt revascularization and in growth of new cells 
may contribute  to the  clearance of bacteria. [4] Some biolo gic grafts have been 
shown to remain int act in the setting of active infection without requiring removal 
when exposed or infected. [31, 40, 43, 45 -47]  Addition ally, some  clinical reports 
note patients were able to be managed non-surgically even when the  patients’ 
wounds b ecame infected. [31, 38, 45 -47] 
 
In addition to s electing specific hernia repair materials, su rgeons give consideration 
to the  placement of repair material as there is evidence that the anatomical location 
of the graft is impo rtant.  There are three general locations for placing the graft, 
including  onlay, inlay, and und erlay positions, and most h ave found the  underlay 
technique  to be  the better technique  when compl ete fascial closure can be achieved 
based on the  lower rate of re-herniation. [4]  It is b elieved that intra-abdomin al 
forces are distributed more evenly across the  repair material when placed in the 
underlay position as the intra-abdomin al pressures push the  repair material into the 
defect and against the  native tissue  rather than away from the  defect. [4, 42]  
 
 
1.2. Rationale  
 
This stu dy aims to p rospectively explore the use of XenMatrix™ AB Surgical Graft for 
ventral or incision al midline  hernia repair in patients across all wound classes (“All 
Com ers”) through 24 m onths post repair. 
 
The device that will be  utilized in th is study (XenMatrix™ AB Surgical Graft) is 
intended for implantation to reinforce soft tissue  where weakness exists and for 
surgical repair of damaged or ruptured soft tissu e, includin g: abdomin al plastic and 
reconstructive surgery; muscle flap reinforcement; hernia repair including abdomin al, 
inguinal, femoral, diaphragmatic, scrotal, umbili cal, and in cision al hernias.  The 
Rifampin and Mino cycline coating has been shown in preclinical in vit ro and in vivo 
testing  to reduce or inhibit mi crobial colonization on the  device.  The claim of 
reduction of  bacterial clearance of the device has not b een establish ed with human 
clinical data, nor has a clinical imp act associated with this claim been demonstrated. 
 
Preclinical in vivo studi es demonst rated an average of 4 log reduction of  microbial 
coloni zation against gram-positive  Methicillin-resistant Staphylococcus aureus 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 4 of 42  
  
 
(MRS A) and an average of 4 log  reduction against gram-negative Escherichia coli (E. 
coli). In vitro speed-to-kill testing  demonst rated a minimum 4 log  reduction against 
gram-positive  MRSA  and M ethicillin-resistant Staphylococcus epidermidis (MRS E) 
and gram-negative Enterobacter aerogenes (E. aerogenes) and E. coli. [48] These 
preclinical efficacy results cannot be  consid ered predictive of clinical performance. 
Clini cal studi es to evaluate performance and risk of infection h ave not b een 
performed. 
 
 
 
1.3. Device Description 
 
XenMatrix™ AB Surgical Graft is an acellular, sterile, non -pyrogenic porcine dermal 
matrix packed dry for use in the  reconstruction of  soft tissue  deficiencies. The device 
surfaces are coated with the  antibacterial agents R ifampin and Mino cycline in a 
bioresorbable L-Tyrosine  succinate polymer carrier. The product has an orange surface 
and minor  non-uniform color variation on the  product surface (“freckles”) that is 
normal. 
 
The coating is shaded orange in color from the  antimi crobial agents. In preclinical in 
vitro and in vivo t esting, the antimi crobial agents reduce or inhibit mi crobial 
coloni zation of  the product during the initial healing process for up to 7 d ays following 
surgery. Absorption of  the resorbable polymer carrier for the antimi crobials is 
compl ete in approximately 12 months.  
 
 
2. STUDY OBJE CTIVES 
 
The objective of this stu dy is collect data on the  performance and use of XenMatrix™ 
AB Surgical Graft for up to 24 months in subj ects with ventral or incision al midline 
hernias, across all CDC wound classes in the  retro-rectus or  intraperitoneal location. 
 
 
3. STUDY ENDPOINTS 
 
 
3.1. Primary Endpoint  
 
1. Wound Occurrences in the first 45 d ays post -implantation. 
Wound Occurrences will be defined as surgical site infection, s eroma, wound 
dehiscence, skin n ecrosis and fistulas requiring intervention  
 
 
3.2. Seconda ry Endp oints 
 
The secondary endpoints  of this stu dy are as follows: 
 
1. Wound Occurrences >45 days post -implantation 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 5 of 42  
  
 
2. Rate of hernia recurrence 
3. Rate of reoperation due  to the  index hernia repair 
4. Carolinas Com fort Scale® and SF -12® 
5. Return to Work 
6. Length of Stay 
 
 
4. STUDY DESIGN 
 
This is a  prospective, multicenter, single-arm clinical study to collect data on the 
performance and use  of XenMatrix™ AB Surgical Graft for ventral or incision al 
midline  hernia repair across p atients in all CDC wound classes utili zing retro-rectus or 
intraperitoneal placement of mesh. The study will be  condu cted at approximately 10 
U.S. sit es to t reat approximately 75 subj ects. Follow-up visits will be  condu cted at 1, 
3, 6, 12, 18 and 24 month (s) following surgery. See Section 6 for a detailed schedule 
of study visits and procedures. 
 
 
5. STUDY POPULATION  
 
 
5.1. Number Of Subjects 
 
This stu dy is projected to enroll up to 75 subj ects at approximately 10 sit es. 
 
 
5.2. Eligib ility Criteria 
 
 
5.2.1.  Inclusion C riteria 
 
1. Subject must be  ≥18 years of age. 
2. Subject must be  willing  and able to give written informed consent. 
3. Subject must be  diagnosed with a ventral or incisional midline  hernia. 
4. Mesh must be  placed in the retro-rectus or  intraperitoneal plane. 
5. Subject must be  willing  to und ergo open hernia repair and be  able to und ergo 
all oth er study procedures as outlin ed in this p rotocol. 
 
 
5.2.2.  Exclusion C riteria 
 
1. The use of surgical graft as a bridge repair. 
2. The subject has mo re than 4 p rior recurrences. 
3. Subject has a contraindication for the placement of surgical graft. 
4. Compl ete removal of existing  mesh from a  prior hernia repair (in the same 
affected area) is not possibl e. 
5. The study hernia repair requires mo re than a single piece mesh (including 
sufficient ov erlap beyond margins of the defect on all sid es). 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 6 of 42  
  
 
6. Subject has intact permanent mesh adjacent to the current hernia to be 
repaired. 
7. Subject has peritonitis at the time of surgery. 
8. The subject is an active smoker within the  last 2 weeks prior to su rgery. 
9. Clini cally significant COPD or heart failure, defined as marked limit ation in 
ability or inability to perform activiti es of daily living. 
10. Subject had chemoth erapy within the  last 12 months, is on or  suspected to be 
placed on chemoth erapy medications du ring any part of the study. 
11. Chronic steroid use  (>6 months)  or immunosupp ression d rugs. 
12. Subject’s body mass ind ex (BMI) >45 kg/m2. 
13. Subject has cirrhosis, and/or ascites. 
14. Subject has a defined collagen diso rder. 
15. Known to be  infected with hum an immunod eficiency virus (HIV). 
16. Subject has clinically significant (not b ased sol ely on creatinine  levels) 
kidney disease that limits ADL, is on h emodi alysis or peritoneal dialysis. 
17. Subject is American Society of Anesthesiology (ASA) Class 4 or  5. 
18. Subject has a life expectancy < 2 years at the time of enrollment. 
19. Subject is p regnant, breastfeeding or planning on becoming  pregnant during 
the course of the study. 
20. Subjects with kno wn sensitivi ty to po rcine products. 
21. Subjects with allergy, history of allergy or hypersensitivi ty to tetracyclines 
(including  mino cycline) or rifamycins (including rifampin ). 
22. Subject has any condition in the  opinion of  the Investigator that would 
preclude the use of the study device, or preclude the subject from compl eting 
the follow-up requirements. 
 
 
6. STUDY PROCEDURES 
 
 
6.1. Subject Screening And Bas eline Evalua tion 
 
Subjects with a diagnosis  of ventral or incision al midline  hernia requiring surgical 
repair will be  screened for eligibility against the study protocol inclusion and 
exclusion criteria utilizing ordinary standard of care procedures (e.g., limit ed physical 
examination typical for hernia patients, blood work (if necessary), medical evaluation, 
etc.) which occurred within 60 d ays of the date of consent. This m ay include a full 
anesthetic work-up, customary for hernia repair procedures. Any other standard of 
care examination or  evaluation within 60 d ays of the date of consent may be 
consid ered baseline for study purposes.  Prior medical records do cumenting these 
tests, examinations and evaluations m ay be used as the source documents for the 
baseline visit.  
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 7 of 42  
  
 
During the screening and recruitment process, the  Investigators will be  responsible  for 
describing the nature of the clinical study, verifying that the eligibility criteria have 
been met, and obt aining informed consent. Written informed consent and a Health 
Insurance Portability and Accountability Act (HIPAA) waiver must be  obtained prior 
to performance of any protocol sp ecific procedures. 
 
The following specific procedures will be  condu cted and do cumented: 
 
 
6.1.1.  Informed Cons ent 
 
All subj ects or legally authorized representatives will provide  written informed 
consent for the study prior to collection of  study data or performance of study 
procedures. A signed copy of the informed consent form (ICF) must be  given to the 
subject. 
 
 
6.1.2.  Enrollment 
 
Subjects who si gn an informed consent will be  considered provision ally enrolled until 
all eligibility criteria have been successfully met, at which time  subjects will be 
consid ered formally enrolled. Subjects who do not m eet all eligibility criteria will be 
consid ered screen failures. 
 
 
6.1.3.  Eligibility 
 
The subject’s eligibility for study enrollment will be  reviewed and documented on the 
appropriate electronic case report form (eCRF ).  At the time of screening, a related 
progress note  should be  recorded in the  medical records to indi cate that all study 
eligibility criteria were reviewed with the screening results not ed. 
 
Subjects who fail to m eet eligibility criteria should be treated according to the 
Investigator’s standard of care practices. Study participation will end at the time of 
eligibility failure.  Data will be  collected for all subj ects who fail to m eet eligibility 
criteria from the  time the informed consent is si gned until the  subject is d etermined to 
have failed screening. At a minimum, the  following information should be  collected 
for all subj ects who fail to m eet study eligibility criteria: 
 
• Subject demographics 
• Reason for screen failure 
• Serious adverse events (followed until resolution or  stabilization)  
 
 
6.1.4.  Assignment of Subject Number 
 
A unique  identification number will be  given to each stu dy subject at the time the 
subject provides informed consent.  Subj ect numb ers will be  assigned in a  sequential 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 8 of 42  
  
 
order.  The subject num ber will consist of  six digits where the first three digits 
designate the study site and the  last three digits designate the subject by number in 
sequential order. 
 
 
6.1.5.  Demographics And Medical History 
 
The subject's medical history and demographic information will be  documented on the 
appropriate eCRF. Demographic information will include sex, date of birth, race and 
ethnicity. 
 
Medical histo ry information will include a review of ventral or incision al hernia 
related events and details (including  previous int erventions)  and lo cation of  hernia, 
and previous abdomin al surgery. 
 
 
 
6.1.6.  Physical Examination 
 
A standard physical exam, appropriate to subj ects about to und ergo abdominal 
surgery, will be  performed by the physician.  Height and weight measurements will be 
recorded to allow for the calculation of  BMI.  The subject’s ability to participate and 
meet the follow-up requirements will be  established. 
 
 
6.1.7.  Quality of Life Assessment 
 
Subjects will compl ete the Carolinas Com fort Scale® and SF-12® to establish b aseline 
measures for quality of life assessments. Occupational status will also be  collected. 
 
 
6.2. Index Procedure 
 
The following section d escribes the surgical techniques that are recomm ended for this 
study.   Sin ce bridging a defect with a graft is not  allowed, several release techniqu es 
are recomm ended; ho wever, other surgical techniques may be applied at the surgeon’s 
discretion.  Sponsor  representatives may attend the index procedures conducted und er 
this p rotocol. 
 
 
6.2.1.  Perioperative Care 
 
Since the lowest incidence of post-operative infection is associated with administ ration 
of an antibiotic  within one  hour prior to incision, prophylactic antibioti cs are to be 
administ ered within one  hour prior to su rgery (first skin in cision)  and two (2) hours 
before if the antibiotic  is a fluoroquinolone  or vancomycin (according to the Surgical 
Care Improvement Program [SCIP]). [51]  Prophylactic antibioti cs should be 
discontinu ed less than 24 hou rs after anesthesia end time  as prolong ed administration 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 9 of 42  
  
 
of antibioti cs can lead to the developm ent of antimicrobial resistant pathogens and an 
increased risk of  C. di fficile infection. [51] 
 
6.2.2.  Abdomin al Wall Reconstruction/Ventral or Incision al Hernia Surgery 
CDC Guidelines 
Intraoperative abdomin al prep is to be  performed according to the  nationally 
recognized standard, CDC Guideline for Prevention of  Surgical Site  Infection. [49]  If 
not already receiving  therapeutic antimi crobial agent perioperatively for an establish ed 
infection, su rgical antimicrobial prophylaxis (AMP) should be  given just before the 
operation b egins and timing  should be  based on s urgeon practice but, at a minimum, 
until b actericidal concentration of  the drug in serum and tissu es is establish ed by the 
time the skin is in cised. Therapeutic levels shou ld be maintained in both s erum and 
tissues throughout the  operation and until, at most a  few hours after the incision is 
closed in the  operating room.  These guidelines are as specified in the  CDC Guideline 
for Prevention of Surgical Site  Infection. [49] The type of AMP administ ered will be 
according to hospit al protocol and su rgeon decision and should be  documented. All 
perioperative and posto perative antibioti cs given to the  subject should be  documented. 
 
Adhesiolysis & Measurement of the Defect 
Once the adhesiolysis is  performed and all of the ventral or incision al hernia has been 
exposed, the  largest vertical and transverse dimensions should be  recorded. 
 
Minim ize Bioburden 
Every effort should be  made to minimi ze the bacterial burden and risk of  post- 
operative compli cations in cluding  debridement of non-viable tissue, abdominal 
washouts, careful preservation of  blood supp ly to the  skin, and compl ete removal of all 
prior mesh (as applicable). 
 
Ventral or Incision al Hernia Repair 
If necessary, resect/debride the edges of the rectus fascia until h ealthy well- 
vascularized tissue  is identified to ensure proper apposition of  the midline  as it is 
closed. 
 
If a retro-rectus approach is preferred and the midline  can be closed primarily, the 
peritoneum or  posterior rectus sh eath should be  carefully dissected creating a  retro- 
rectus po cket for the XenMatrix™ AB Surgical Graft to be  placed. 
 
If further release is needed to close the midline  every effort should be  made to do so 
including  the use of the TAR technique  [50]. Care must be  taken not to damage the 
blood supp ly and the  nerves.  Once the dissection is compl ete the peritoneum/ 
posterior rectus sh eath should be  closed and the  XenMatrix™ AB graft should be 
placed in the  retro rectus space according to the  instructions for use (IFU). 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 10 of 42  
  
 
If intraperitoneal graft placement is p referred (and the midline  can be closed by any 
means (including CST)), place the graft intraperitoneally and close the fascial edges of 
the defect anterior to graft. 
 
The defect will be  closed and a minimum 5 cm ov erlap on every side shou ld be 
factored in to d etermine  the minim al patch size. The entire defect must be  covered. 
The patch will be  fixated using  sutures.  If the hernia repair requires mo re than a single 
piece of surgical graft (with adequate overlap beyond the  margins of  the defect on all 
sides) the subject is excluded from the  study. 
 
Closu re should be  performed with permanent or long lasting sutures every 1-2 cm 
between sutu res, for example  with an interrupted Figure-8 closure or running stitch. 
 
If a previous s car of skin is p resent, the  scar should be  excised. The fascial and 
subcutaneous l ayers sho uld be  closed with sutu res.  The skin should be  closed with 
staples and/or  sutures (1-2 cm between sutu res preferred). 
 
 
6.2.3.  Immediate Postop erative Care 
After surgery, study subjects will be  given postop erative instructions for care of the 
ventral or incision al hernia repair site based on the  Investigator’s typical protocol. 
Prescription m edication should be  what is no rmally prescribed to ventral or incision al 
midline  hernia repair study subjects.  Stu dy subjects should be  asked to u se 
prescription and non -prescription d rugs on an as needed basis on ly. 
 
The Investigator will determine  the extent of individu al activity that is appropriate, 
including  lifting and oth er forms of  physical exertion. 
 
 
6.2.4.  Surgical Details 
 
Surgical details will be recorded and entered in the  appropriate eCRF(s).  Details m ay 
include but are not be  limited to: ASA score, size of the defect, procedure start/stop 
time (skin to skin ), perioperative antibioti cs (including dose and timin g), concomitant 
procedures (e.g., panniculectomy), was closure achieved (midlin e, fascia, skin) 
hospit al length of stay, and adverse events in cluding device or procedure related 
compli cations and mo rtality. 
 
 
6.3. Subject Follow-up 
 
Subjects who si gn the  informed consent and meet eligibility criteria but who do not 
undergo the  XenMatrix™ AB Surgical Graft placement surgery per-protocol should be 
treated per hospit al standard of care.  Follow-up will end at the time it is d etermined 
that the ventral or incisional midline  hernia repair surgery utilizing XenMatrix™ AB 
Surgical Graft was not p erformed as planned (i.e., prior mesh could not be  removed). 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 11 of 42  
  
 
However, any study-related adverse events will be reported and followed to 
satisfactory resolution or  stabilization. 
 
Failure of the study procedure must be  documented and su rgical details must be 
recorded on the  appropriate eCRF(s). 
 
 
6.3.1.  Assessments 
 
Subjects should report to th eir respective study site for follow-up visits at the post- 
operative time points b elow: 
 
• 1 month: ± 2 weeks 
• 3 month:  ± 1 month  
• 6 month:  ± 1 month  
• 12 month: ± 2 months  
• 18 month: ± 2 months  
• 24 month: ± 2 months  
 
At each stu dy visit, the  following procedures will be  compl eted: 
 
• Physical exam will be  performed by a study physician to check for wound 
occurrences, hernia recurrence and any other surgical compli cations.  The 
physical exam should also in clude assessment of the subjects’ weight and skin 
appearance over the ventral or incision al midline  hernia repair site. 
▪ A recurrent ventral or incision al midline  hernia will be  defined as any hernia 
identified or confirmed by the investigator, during any study follow-up visit 
(including  unscheduled), within approximately 5 cm of the index hernia. 
▪ Potential recurrent hernias identified via  incidental magnetic resonance 
imaging (MRI) or computed tomo graphy (CT) scan will be  evaluated by the 
operating surgeon for clinical significance. 
▪ If an infection is susp ected, a routine  culture shall be obtained via  the 
instructions in Appendix 18.2.  Classification will follow  the CDC guidelines 
for superficial and deep surgical site  infections in  Appendix 18.3.  
▪ Return to Work 
▪ Carolinas Com fort Scale® 
▪ SF-12® 
▪ Assessment and do cumentation of  adverse events/compli cations.  
 
A subject who has a re -operation at the index surgical site, or has the repair site 
surgically impacted in any way, may be withdrawn from the study upon discharge from 
hospitalization for such re -operation or other surgical intervention. Site personnel wil l be 
responsible for documenting, on the applicable eCRF, any adverse events or other post -
procedural complications that the subject may have encountered during the hospitalization 
and up to 30 days post -re-operation  
 
 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 12 of 42  
 6.3.2.  Unscheduled Visits 
 
Unscheduled visits are visits in addition to the  per protocol stu dy schedule, at the 
request of the subject or study personnel to address intercurrent problems or 
concerns. 
Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018 
CON FIDENTIAL Page 13 of 42  
  
 
If the subject has an evaluation related to the  abdomen or abdomin al organs at an 
unscheduled visit at any time during the study follow-up period, the  subject will be t reated 
per standard of care.  Any serious adverse events and/or  relevant AEs should be  recorded.  If 
the subject should und ergo imaging for any reason and a recurrent ventral or incision al 
midline  hernia is identified, it must be  recorded as well. 
 
Unscheduled Visits should on ly be compl eted in the  eCRF  if AEs occurred or if this 
is an Early Termination visit. 
CON FIDENTIAL Page 13 of 42  
 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
 
 
6.4. Time And Ev ents Schedule 
 
 
Study Procedure Screening and 
Baseline 
Period  
Surgery 1 
Month 
Visit 3 
Month 
Visit 6 
Month 
Visit 12 
Month 
Visit 18 
Month 
Visit 24 
Month 
Visit  
Unscheduled 
Visit1) 
 
Visit Window (days) Within 60 days 
of consent  
0  
16-44  
60-120  
150-210  
305-425  
485-605  
670-790  
-- 
 
Describe study to potential subject  
X         
 
Obtain informed consent  
X         
 
Verify eligibility criteria  
X  
X        
Collect demographics and medical 
history  
X         
 
Conduct physical examination  
X   
X  
X  
X  
X  
X  
X  
X 
 
Placement of Device   
X        
Return to Work, Carolinas Comfort 
Scale®, SF-12®  
X   
X  
X  
X  
X  
X  
X  
X 
 
Collect adverse events/complications  
X  
X  
X  
X  
X  
X  
X  
X  
X 
 
1) Only to be completed in eCRF  if subject experienced AE or if this is an Early Termination visit. 
CON FIDENTIAL Page 14 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
6.5. Subject Discontinua tion 
 
Subjects may be discontinu ed for the following reasons:  
 
• Subject has device explanted. 
• Subject is Lost to Follow-Up (LTFU): A subject may be consid ered LTFU if the 
investigational site  personnel are unable to locate the subject despite  two documented 
attempts to noti fy the subject via telephone  and a third attempt by certified mail. 
• Subject consent is withdrawn: The subject requests to t erminate his/h er participation in  
the study (the Investigator must attempt to id entify and do cument the  reasons for 
termination). Subj ects will be  informed that they have the right to withdraw from the 
study at any time, for any reason, without affecting their future care. 
• Study termination: The study is terminated by Sponsor. 
 
Once a subject discontinu es from the  study, the Investigator must compl ete a Study 
Compl etion eCRF  and the  reason for subject discontinu ation must be  fully documented. 
 
 
6.6. Replacement of Subjects 
 
A subject that discontinu es from the  trial will not be replaced. 
 
 
7. ADV ERSE E VENTS 
 
The Investigator is responsible  for the detection and do cumentation of  events m eeting the 
criteria and definition of  an AE or SAE, as provided in this p rotocol. All AEs that occur during 
the study should be  treated with establish ed standards of  care that will protect the life and 
health of  the study subjects. 
 
AEs will be  collected from the  time of enrollment (AE onset after signing ICF) through the  end 
of study participation (either study compl etion or  early discontinu ation)  and will be 
documented in the  medical record or source document and on stu dy eCRFs. All events will be 
followed to s atisfactory resolution or  stabilization. 
 
 
7.1. Definition of  Events 
 
In this study, an AE is defined as any undesirable clinical event occurring in the abdomin al 
space including the lower abdomin al, inguinal and pubic  regions (including the skin), as well 
as any other undesirable clinical events judged to be related to the study device or surgical 
procedure regardless of anatomical region. Abnormal laboratory results are not to be 
consid ered AEs unless the results are accompanied by clinical signs or symptoms.  The 
Investigator will assess the relationship  of an AE to the study device or procedure as described 
in Section 7.3.  
CON FIDENTIAL Page 15 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
7.2. Definition of  Serious Adverse Events (SAE) 
 
An event will be  classified as a serious adverse event (SAE) if it meets the  definition of  serious 
injury or illness in the  Medical Device Reporting Regulation [21 C FR 803.3]  as listed below: 
 
• Is life-threatening, 
• Results in p ermanent imp airment of a body function or  permanent damage to a body 
structure, 
• Nece ssitates medical or surgical intervention to  preclude permanent imp airment of a 
body function or  permanent damage to a body structure. Permanent means irreversible 
impairment or damage to a body structure or function, excluding  trivial imp airment or 
damage. 
 
NOTE :  The term serious is not synonymous with severity, which may be used to d escribe the 
intensity of an event experienced by the subject. 
 
 
 
7.3. Relationship Of Adverse Event To Device/Procedure 
 
Assess each AE for its relationship to the  device (XenMatrix™ AB Surgical Graft) or surgical 
procedures as follows: 
• Device: This category should be  restricted to AEs directly attributable to devices used 
as part of the study procedure. 
• Procedure: This category should be  restricted to AEs directly attributable to the  study 
device surgical procedure. 
 
Use the following categories for assigning the certainty of the relatedness: 
 
• Definitely Related:  An AE is definitely related if it is obvious, certain or there is little 
doubt regarding the relationship.  
 
• Possib ly Related:  An AE is possib ly related if it is capable of being related but 
relatively unlik ely. 
 
• Not Related:  An AE is not related if it is d etermined that there is no pl ausible 
association. 
 
 
 
7.4. Severity of Adverse Events 
 
Each AE should be  assessed for its severity, or the intensity of an event, experienced by the 
subject. 
 
• Mild:  Aware ness of a sign or symptom th at does not int erfere with the  subject’s activity 
or is transient and is resolved without t reatment or sequelae. 
CON FIDENTIAL Page 16 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 
• Mod erate:  May interfere with the  subject’s usu al activity. 
 
• Severe:  Symptom (s) causing severe discomfort and si gnificant imp act of the subject’s 
usual activity and requires treatment. 
 
 
7.5. Reporting Of Events 
 
If an AE occurs, all sections of  the appropriate eCRF must be  compl eted.  In addition, 
all AEs will be  classified by the investigator according to the  Clavien-Dindo Grading 
System for the Classification of  Surgical Compli cations to elimin ate subjective 
interpretation of  adverse events and any tendency to do wn-rate compli cations.  
 
All Investigator-judged device-related AEs that occur (whether serious or  not) must be 
reported to Davol Inc. Field Assurance using  the contact information p rovided in S ection 8, 
within 24 hou rs of becoming  aware of the event. 
 
Addition ally, all SAEs (regardless of relationship)  must be  reported to the  Sponsor  within 24 
hours of becoming aware of the event by sending an email to XenAB@crbard.com. 
This email should contain the  following minim al information: 
- short description of  the SAE 
- device/procedure relationship 
- date SAE occurred 
 
- date of awareness 
It is the  responsibili ty of the Investigator to inform the  Institution al Review Board (IRB) of 
AEs according to IRB requirements. The Sponsor  will report to the  Food and Drug 
Administ ration (FDA) as appropriate after becoming aware of a reportable event. 
 
 
8. MECHANICAL FAILURES, MALFUNCTIONS AND DEFECTS 
 
The Investigator will record if a Sponsor  device used in the  study procedure failed to m eet its 
performance specifications whether due to mechanical failure, malfunction or defects. This 
applies to: d evices used in the  subject, devices in which the  package was opened but the  device 
was not us ed for implantation in the  subject, or devices with which impl antation was 
attempted, but the  device did not remain (was not  used) in the  subject. 
 
A recurrence (unless it is in a  different location than the  study hernia) is considered a device 
failure if the recurrence is considered to be  possi bly device related and not  proce dure related, 
or an issue  of patient mi smanagement (e.g., use  of a Vacuum Assisted Clo sure (V.A.C.) system 
for too lon g; graft used was too sm all to adequately cover the defect, etc.), as determined by  
the Investigator. 
CON FIDENTIAL Page 17 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
All mechanical failures, malfunctions, missing  components, or  any other defect of 
XenMatrix™ AB Surgical Graft, or any compon ents of  the device kit th at do not p erform to 
specifications must be  prompt ly reported to Davol: 
 
Field Assurance Department 
e-mail: Davol.FieldAssurance@crbard.com 
 
The event must also be  documented on the  Device Failure eCRF  and the  malfunctioning  device 
should be  retained for return and evaluation to Davol Field Assurance. 
 
 
9. RISK/BENEFIT ANA LYSIS 
 
The device that will be  utilized in th is study (XenMatrix™ AB Surgical Graft) has 510 (k) 
clearance from the  U.S. Food and Drug Administ ration and is int ended for implantation to 
reinforce soft tissue  where weakness exists and for surgical repair of damaged or ruptured soft 
tissue, includin g: abdomin al plastic and reconstructive surgery; mus cle flap reinforcement; 
hernia repair including abdomin al, inguinal, femoral, diaphragmatic, scrotal, umbili cal, and 
incision al hernias. 
 
The study subjects participating in this stu dy will require ventral or incisional midline  hernia 
repair surgery as part of their standard of care. The usual risks of  ventral or incision al midline 
hernia repair apply independent of the procedures required under this p rotocol. The known 
possible  risks associated with the  use of the XenMatrix™ AB Surgical Graft are outlin ed in the 
IFU (attached). 
 
Collection and analysis of  the data generated in this stu dy may be of benefit to future subjects 
who require ventral or incision al midline  hernia repair. 
 
 
10. CASE REPORT FORMS 
 
The Investigator is responsible  for ensuring the accuracy and compl eteness of all stu dy 
documentation.  All clinical study data will be  recorded in the  eCRFs provided to the 
investigational site. 
 
 
11. STATISTICAL METHODS 
 
This section d escribes the planned statistical analyses for this stu dy. A detailed Statistical 
Analysis Pl an (SAP) will be  compl eted and placed on file prior to database lock. The SAP will 
contain a comprehensive  explanation of  the methodolo gy used in the  statistical analyses 
described below. 
 
 
11.1. Study Hypo thesis 
There is no formal statistical hypothesis for this stu dy. The study will follow eligible 
patients across all CDC wound classes who un dergo ventral or incision al midline  
CON FIDENTIAL Page 18 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
hernia repair with the  XenMatrix™ AB Surgical Graft in o rder to assess wound 
occurrences. 
 
 
11.2. Sample Size Consid erations 
 
This stu dy is projected to enroll up to 75 subj ects at approximately 10 sit es in order to 
have 64 evaluable subjects at 24 months.  It is anticipated that there will be  a 15% loss 
to follow-up rate.  The sample  size of 64 evaluable subjects is b ased on pot ential 
adequacy of data to meet the study objectives. It is not b ased on any statistical 
consid eration. 
 
 
11.3. Data Analysis  
 
11.3.1.  Analysis Popul ation 
The Intent-to-treat (ITT) popul ation consists of  all enrolled subj ects who have signed 
the Informed Cons ent Form. The modi fied ITT (mITT) popul ation is d efined as those 
subjects in the  ITT popul ation whom und erwe nt placement of a XenMatrix™ AB 
Surgical Graft.  Subj ects who are enrolled but not  treated with XenMatrix AB will be 
replaced to ensure 75 su bjects are treated with the  study device. All analyses will be 
primarily based on the  mITT popu lation. 
 
Demographics and baseline characteristics will be  summ arized using  the mITT 
popul ation. Summ ary statistics for categorical variables will include frequency counts 
and percentages and for continuous v ariables mean, standard deviation, minimum, 
median and m aximum.  
 
Subjects who do not receive XenMatrix™ AB Surgical Graft will have their AEs 
summ arized separately and their outcome data will not be  collected or analyzed. 
 
 
11.3.2.  Primary Endpoint  
The primary endpoint of  wound o ccurrence rate will be  assessed within the  first 45 
days post -implantation.  Wound o ccurrences are defined as surgical site  infection, 
seroma, wound d ehiscence, skin n ecrosis and fistulas requiring intervention. 
 
 
 
11.3.3.  Secondary Endpoints  
The following secondary endpoints will be  evaluated: 
 
1. Wound o ccurrences > 45 days post -implantation 
2. Rate of reoperation due  to the  index hernia repair 
3. Carolinas Com fort Scale® and SF -12® 
4. Return to Work 
5. Length of Stay 
CON FIDENTIAL Page 19 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
For each of the above  listed secondary endpoints,  estimates along with th eir 95% 
confidence intervals of the variable of interest based on the  mITT popu lation will be 
reported. 
 
 
11.4. Data Analysis Consid erations 
 
11.4.1.  Data pooling  
Data from all inv estigational sites will be  pooled for analysis. Sit es will be  tested for 
potential differences in the primary endpoint.  Sites with fewer than 10 t reated subj ects will 
be combin ed for this pu rpose. If there is significant variation among  sites, the rates of the 
primary endpoint and associated 95%  confidence interval will be  estimated using  a logistic 
regression with sit es included in the  model as a random effect. 
 
 
11.4.2.  Handling  of missing  data 
Study endpoints  may be missing  due to withdrawal of consent, investigator’s decision,  lost 
to follow-up, device explanted and death. As long as the missing  data is unrelated to the 
study intervention,  limiting the analysis to those  subjects who contribute  endpoints 
produces unbiased estimates of the event rates. The reason for missing  data for all subjects 
will be reported. The primary analysis will be performed without  imput ation for the 
missing  data. As secondary analysis, the rates of the primary endpoint  will be estimated 
using  Kaplan Meier method that will account the time at risk prior to discontinu ation of the 
study. 
 
 
11.5. Interim Analysis  
 
An interim analysis of  some  or all stu dy endpoints will be  performed after all active 
subjects have a 12-month visit. However, interim analyses may be performed at other time 
periods (e.g., 6-months)  to assess the  results.  There is no st atistical imp act of the interim 
analysis. i. e. the study will continue  as originally planned and will not be  affected in any 
way by the result of  the interim analysis. All study  endpoints will be  summarized for 12- 
month follow-up at interim analysis. 
 
 
12. ADM INISTRATIVE REQUIREMENTS 
 
This clinical study will be  condu cted in accordance with the  Declaration of  Helsinki, HIPAA 
requirements, Good Clini cal Practice, and applicable FDA regulations (21 CFR Parts 50, 54, 
and 56 ). 
 
 
12.1. Investigator Selection 
 
The Investigator must be  of good st anding as an Investigator and kno wledgeable in relevant 
areas of clinical research to ensure adherence to the requirements of  the protocol, in cluding 
the protection of  human subjects.  Other site personn el must h ave appropriate research 
experience and infrastructure to ensure adherence to the  protocol and enrollment of 
CON FIDENTIAL Page 20 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
sufficient numb ers of evaluable subjects. The curriculum vit ae (CV) of the Investigator(s) 
will be  maintained in the  Sponsor  files as documentation of  previous m edical training. 
Federal databases will be  searched to ensure that the Investigator(s) and/or  the site are not 
prohibit ed from engaging in federally sponso red clinical research.  The Investigator will 
sign the  signature page of this p rotocol, agreeing to comply with all applicable government 
regulations and the  requirements of  this stu dy. 
 
 
12.2. Regulatory and E thical Consid erations 
 
 
12.2.1.  Institution al Review Board (IRB) Approval 
 
Before comm encement of the study, the Investigator must p rovide  Sponsor  with 
written documentation of  IRB approval.  This approval must refer to the  ICF and 
the study by both the  title and the  protocol numb er assigned by the Sponso r.  The 
Investigator, if a member of the IRB, is not to p articipate in the  approval decision 
for this stu dy. This non -participation should be  noted in the  approval letter. 
 
No device suppli es, if applicable, will be  shipp ed to the  Investigator until the  IRB 
approval has been suppli ed to Sponso r. 
 
The IRB must  give written renewal of the original approval at least annually to 
continue  the study.  A copy of the written renewal must be  provided to Sponso r. 
 
As appropriate, amendments to the  protocol must also be  approved by the IRB 
before implementation at the sites, unl ess warranted to elimin ate an immediate 
hazard. 
 
 
12.2.2.  Informed Cons ent and HIPAA Authorization 
 
Prior to any study procedure, the Investigator (or designee) must explain to each 
subject in layman’s terms, the  nature of the study, its pu rpose, expected duration, 
and the  risks and benefits of  study participation.  Also, subj ects will be  informed 
of uses and dis closures of their medical information for research purposes, and 
their rights to access information about th em. The subjects must be  informed of 
their right to withdraw from the  study at any time and for any reason without 
sanction, p enalty, or loss of benefits to which they are otherwise entitled, and that 
withdrawa l from the  study  will not j eopardize their future medical care. After this 
explanation and before any study procedure is conducted, and before entering the 
study, the subject (or legally authorized representative) must volunt arily sign and 
date the IRB-approved ICF and HIPAA Cons ent Form in accordance with 21 
CFR Parts 50 and 56.  The subject will receive a copy of their ICF and HIPAA 
Cons ent Form. 
CON FIDENTIAL Page 21 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
12.3. Protocol Adherence And Deviations 
 
The study will be  condu cted as described in this p rotocol. Any deviations from this 
protocol must be  documented by the Investigator.  If an emergency situation arises in 
which the  safety and welfare of a subject may require immediate alternative intervention, 
the Investigator should act in the  best int erests of  the subject.  The Sponsor  and the  site’s 
IRB must be  notified imm ediately if this o ccurs.  All noti fications should be followed 
with written confirmation that describes the emergency action and out comes.  Written 
confirmations should be  sent to Sponsor  and the  IRB within 10 busin ess days from the 
date of the emergency action. 
 
 
12.4. Device Accountabili ty 
 
The Investigator will ensure that the device components are stored und er the conditions 
outlin ed in the  IFU and maintained und er secure storage. Device accountability records 
will be  maintained and monito red.  Study devices may not be  re-sterilized or reused. 
 
 
12.5. Data Collection 
 
The Investigator is responsible for compl etely and accurately recording study data in the 
appropriate sections of  the eCRFs provided by Sponso r.  The eCRFs must  be signed by 
the Investigator or by his/her documented designee. 
 
The investigator is also responsible  for making source documents and forms readily 
available for a thorough review by the study monitor  at each monito ring visit.  The 
monitor  will ensure the accuracy of data recording at each investigational site by 
comparison to suppo rting sou rce documents du ring periodic  site visits.  Adherence to 
proper recording of information as well as assuring that corrections are being made will 
also be  addressed during these periodic  visits.  
 
 
12.6. Subject Compensation 
 
To compensate subjects for their time and participation, th ey may receive stipends upon 
compl etion of  each of the protocol sp ecified stu dy visits.  If the subject does not compl ete 
a visit, compensation will not be  provided for that visit.  
 
 
12.7. Communications Wi th The  Sponsor 
 
Althou gh the  Investigator and his/h er staff may have contact with key individuals at the 
Sponsor  throughout the  course of the study, all communi cations regarding condu ct of the 
study must be  channeled through the  Sponso r’s clinical affairs personnel or their 
designees.  The Sponsor  contact listed on the  title page of this p rotocol sh ould be 
contacted first with any matters regarding the conduct of this stu dy. 
CON FIDENTIAL Page 22 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
12.8. Required Documentation 
 
An Investigator may not screen or enroll subj ects until authorized to do so  by the 
Sponso r.  At a minimum,  the following documentation must be  received by the Sponsor 
prior to stu dy comm encement: 
 
• CVs and m edical licenses for the principal Investigator and Sub -Investigator(s); 
• signed Clini cal Study Agreement; 
• signed Nondis closure Agreement; 
• signed Protocol Signature Page; 
• written approval from the  IRB of both the  protocol and in formed consent form; 
• signed Financial Disclosure Statement; and, 
• IRB Assurance of Compli ance Form or equivalent. 
 
 
12.9. Publications 
 
At the conclusion  of the Study, a multi -center journal article may be prepared for 
publi cation in a reputable scientific journal. The publi cation of the principal results 
from any single-center experience within the study is not allowed until the preparation 
and publi cation of the multi -center results.  Exceptions  to this rule require the prior 
approval of Bard. The analysis of other pre-specified and ad hoc endpoints  will be 
performed by Bard or its designee. Such analyses, as well as other propos ed 
investigations  will require the approval of Bard. Bard anticipates many secondary 
manuscripts with principal authorship.  For purposes of timely abstract presentation and 
publi cation, such secondary publi cations  will be delegated to the appropriate principal 
authors, and final analyses and manuscript review for all multi -center data will require 
the approval of the Bard. 
 
 
 
13. SITE MONITORING 
 
The study monito rs are designated as agents of  the Sponsor  and are assigned to ov ersee the 
condu ct and progress of the study and to be  the principal communi cation link b etween 
Sponsor  and Investigator. The study monito rs will be involv ed in Investigator selection and 
training, assurance of IRB approvals, and periodic  on-site inspection and monito ring of sites 
and records, to ensure continu ed compli ance with the protocol and adequacy of the 
Investigator and the  facility to carry out the  study.  In addition, the  monitor  will verify that 
the device is being used in accordance with the  protocol inst ructions.  The monitor  will 
perform several types of site visits du ring the course of the study. 
 
The investigational sites may also be  subject to q uality assurance audit by the Sponsor  (and 
its affiliates) and the  Sponsor’s study contractor personn el, as well as by FDA 
representatives.  It is impo rtant that the Principal Investigator and the  relevant inv estigational 
CON FIDENTIAL Page 23 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
site personn el are available during the monito ring visits and possible  audits  and th at 
sufficient time  is devoted to the  process. 
 
 
13.1. Study I nitiation Visit 
 
Before the study begins, the study monitor  will visit the  site. The purpose of this visit 
is to review with the  Investigator and st aff the provisions and proper conduct of the 
clinical evaluation. This includes a detailed review of the protocol and eCRFs with 
instructions as to th eir compl etion, as well as reviewing regulations p ertaining to the 
condu ct of the clinical study.  Arrangements for timely and accurate reporting of 
clinical data and relevant medical events will be  establish ed as well as ensuring safe 
and secure storage for the study devices. 
 
The study monitor  will: 
• confirm that the ICF to be used is the  one approved by the IRB; 
• verify that all necessary documents are on file at the site; and 
• confirm that there are provisions to continue  and m aintain all documents and 
records th roughout the  study as required by good clinical practice regulations. 
 
 
13.2. Ongoing Monitoring Visits 
 
The study monitor  will maintain personal contact with the Investigator and staff 
throughout the  study by telephon e, e-mail, fax, mail, and on -site visits.  On-site 
monito ring will begin after the first subj ects are enrolled and continue  until the study is 
compl eted.  This monito ring will assure continu ed protocol compli ance, adequate 
subject enrollment, accurate data reporting (including the comparison of  eCRFs with 
subject records), device accountability, and continu ed IRB acceptance of the study. 
The study monitor  will evaluate and summ arize the results of  each visit in written 
reports, id entifying any ongoing data problems with any study site and specifying 
recomm endations for resolution of  noted deficiencies. 
 
 
13.3. Final Monitoring Visit 
 
At the compl etion of  the study, the study monitor  will condu ct a final on-site visit.  The 
purpose of this visit is to  collect all outst anding  study data documents, confirm that the 
Investigator’s files are accurate and compl ete, review the record retention requirements 
with the  Investigator, provide for the return of unused devices to Sponso r, review 
records which account for device shipm ents, and assure that all applicable requirements 
for closure of the study are met. The actions and observations m ade at this  visit will be 
recorded and filed. 
 
 
14. TERMINATION  OF STUDY  
CON FIDENTIAL Page 24 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 
Sponsor  reserves the right to susp end enrollment or terminate the study at any time as set 
forth in the  Clini cal Study Agreement. Written notice will be  submitt ed to the  Investigator in 
advance of such termination. 
 
Sponsor  may suspend enrollment or terminate the study at a specific site for reasons 
includin g, but not limit ed to, in adequate data collection, low  subject enrollment rate, 
achievement of the total enrollment, administ rative reasons, or non-compl iance with the 
protocol or other clinical research requirements. 
 
 
15. REPORTING REQUIREMENTS 
 
This stu dy protocol is exempt from 21 C FR 812 as the device is cleared for 
comm ercialization in the  U.S. and the  usage in this p rotocol in on -label.  In addition to the 
AE reporting described above, all sites are also required to submit annual study progress 
reports to the  Sponso r. 
 
 
 
16. RECORD RETE NTION 
 
The investigator shall retain all stu dy records for a period of  two years after the latter of the 
following two dates: the  date on which the  study is terminated or compl eted, or the date a 
marketing application is approved for the indication for which it is b eing investigated.  The 
investigator may withdraw from the  responsibili ty to maintain records for the period required 
and transfer custody of the records to any other person who will accept responsibili ty for 
retaining  them.  Notice of a transfer shall be given to the  Sponsor  not later than 10 working 
days after transfer occurs. 
CON FIDENTIAL Page 25 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
17. REFERENCES 
 
1. Cobb WS, Kerc her KW, Heniford BT. Laparoscopic repair of incision al hernias. Su rg 
Clin North Am 2005 Feb;85(1):91-103. 
 
2. Schuster R, Sin gh J, Safadi BY, Wren SM.  The use of acellular dermal matrix for 
contaminated abdomin al wall defects: wound st atus p redicts success. Am J Su rg 
2006;192 (5):594-597. 
 
3. Poulose  BK, Shelton J, Phillips S, Moo re D, Nealon W, Penson D, Beck W, Holzman 
MD.  Epidemiolo gy and cost of  ventral hernia repair: making the case for hernia research. 
Hernia 2012; 16:179 -183. Epub 2011 S ept 9. 
 
4. Breuing K, Butler CE, Ferzoco S, Franz M, Hultman CS, Kilbridge JF, Ros en M, 
Silverman RP, Vargo D (The Ventral Hernia Working Group).  Incision al ventral hernias: 
review of the literature and recomm endations regarding the grading and technique  of 
repair.  Surgery 2010;1 48(3):544-558. Epub 2010  Mar 20. 
 
5. Geisler DJ, Reilly JC, Vaughan SG, Glennon EJ, Kondylis PD. Safety and outcome of 
use of nonabsorbable mesh for repair of fascial defects in the presence of open bowel. 
Dis Colon R ectum 2003 ;46(8):1118 -1123.  
 
6. Neff M, C antor B, Geis WP. Laparoscopic-assisted primary repair of a complicated 
ventral incision al hernia.  JSLS 2005;9 (2):241-244. 
 
7. Cavallaro A, Lo Menzo E, Di Vita M, Zanghì A, Cavallaro V, Veroux PF, Cappellani A. 
Use of biolo gical meshes for abdomin al wall reconstruction in hi ghly contaminated 
fields.  World J Gastroenterol 2010;16 (15):1928 -1933. 
 
8. Byrnes MC,  Irwin E, Carlson D, Campeau A, Gipson JC, Beal A, Croston JK.  Repair of 
high-risk in cision al hernias and traumatic abdomin al wall defects with po rcine mesh. 
Am Su rg 2011;77 (2):144-150. 
 
9. Luijendijk R, Hop W, van den Tol M et al. Comp arison of  suture repair with m esh repair 
for incision al hernia. New Engl J Med 2000;343 (6):392-398. 
 
10. Anthony T, Bergen PC, Kim L et al. Factors affecting recurrence following incision al 
herniorrhaphy. World J of Surg 2000;24 (1):95-101. 
 
11. Burger J, Luijendijk R, Hop W  et al. Long-term follow-up of  a randomi zed controlled 
trial of suture versus m esh repair incision al hernia.  Ann Su rg 2004;240 (4):578-583. 
 
12. van Geffen H, Simm ermacher R, van Vroonho ven T, van der Werken C. Su rgical 
treatment of large contaminated abdomin al wall defects. J Am Coll Su rg 2005;201:206 - 
212. 
CON FIDENTIAL Page 26 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
13. George C, Ellis H. The results of  incision al hernia: a twelve year review.  Ann R Coll 
Surg Engl 1986;68:185 -187. 
 
14. Ramirez O, Ruas E, Dellon A. “Compon ents separation”  method for closure of 
abdomin al-wall defects: An anatomic  and clinical study. Plast Reconstr  Surg 
1990;86 (3):519-526. 
 
15. DiBello J, Moo re J. Sliding myofascial flap of the rectus abdominis mus cle for the 
closure of recurrent ventral hernias. Plast Reconstr  Surg 1996;98 (3):464-469. 
 
16. Girotto J, Ko M, R edett R et al. Closu re of chronic abdomin al wall defects: a long-term 
evaluation of  the compo nent separation m ethod. Ann Pl ast Su rg 1999;42 (4):385-395. 
 
17. Shestak K, Edington H, Johnson R. The separation of  anatomic  compon ents technique  for 
the reconstruction of  massive midline  abdomin al wall defects: anatomy, surgical 
techniqu e, application and limit ations revisited. Plast Reconstr  Surg 2000;105 (2):731- 
738. 
 
18. Lowe J, Garza J, Bowman J et al. Endos copically assisted “compon ents separation”  for 
closure of abdomin al wall defects. Pl ast Reconstr  Surg 2000;105 (2):720-729. 
 
19. de Vries Reilingh T, Goor H, Rosm an C et al. “Compon ents separation t echnique” for the 
repair of large abdomin al wall hernias. J Am Coll  Surg 2003;196 (1):32-37. 
 
20. Giurgius M,  Bendure L, Davenport DL, Roth JS. The endos copic compon ent separation 
technique  for hernia repair results in reduced morbidity compared to the  open compon ent 
separation t echniqu e.  Hernia. 2011 Aug 11. [Epub ahead of print] 
 
21. Korenkov M, S auerland S, Arndt M, et al. Randomi zed clinical trial of suture repair, 
polypropylene mesh or  autodermal herniopl asty for incision al hernia. Br J Surg 2002; 
89(1):50-56. 
 
22. Petersen S, Henke G, Zimmermann L, et al. Ventral rectus fascia closure on top of  mesh 
hernia repair in the  sublay techniqu e. Plast Reconstr Surg 2004;114 (7):1754-1160.  
 
23. den Hartog D, Dur AHM, Tuinebreijer WE, Kreis RW. Open surgical procedures for 
incision al hernias. Co chrane Database of Systematic Reviews 2008; (3):No.: CD006438. 
DOI: 10.1002/14651858.C D006438.pub2.  
 
24. Dur AH, den Hartog D, Tuinebreijer WE, et al. Low recurrence rate of a two-layered 
closure repair for primary and recurrent midline  incision al hernia without  mesh. Hernia 
2009;13 (4):421-426. 
 
25. Pierce RA, Spitl er JA, Frisella MM, et al. Pool ed data analysis of  laparoscopic vs. op en 
ventral hernia repair: 14 years of patient data accrual. Surg Endosc 2007; 21 (3):378-386. 
CON FIDENTIAL Page 27 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
26. Carlson M A, Frantzides CT, Shost rom VK, Laguna LE. Minim ally invasive ventral 
herniorrhaphy: an analysis of 6,266 publish ed cases. Hernia 2008;12 (1):9-22. 
 
27. Itani KM, Hur K, Kim LT, et al. Comp arison of  laparoscopic and op en repair with m esh 
for the treatment of ventral incision al hernia: a randomi zed trial. Arch Surg 
2010;145 (4):322-328. 
 
28. Forbes SS, Eskicioglu C,  McLeod RS, Okrainec A. Meta-analysis of  randomized 
controlled trials comparing open and laparoscopic ventral and in cision al hernia repair 
with m esh. Br J Surg 2009;96(8):851-858. 
 
29. Jezupovs A, Mih elsons  M. The analysis of  infection after polypropylene mesh repair of 
abdomin al wall hernia.  World J Surg. 2006 Dec;30(12):2270 -8; dis cussion 2279 -2280.  
 
30. Szczerba SR, Dumanian GA. Definitive  surgical treatment of infected or exposed ventral 
hernia mesh.  Ann Su rg 2003;237:437 -441. 
 
31. Kim H, Bruen K, Vargo D. Acellular dermal matrix in the management of high-risk 
abdomin al wall defects. Am J Surg 2006;192:70 5-709. 
 
32. de Vries Reilingh TS, van Geldere D, Langenhorst B, de Jong D, van der Wilt GJ, van 
Goor H, Bleichrodt RP.  Repair of large midline  incision al hernias with polypropylene 
mesh: comparison of  three operative techniqu es. Hernia 2004;8 (1):56-59. 
 
33. Gupta A, Zahriya K, Mu llens PL, Salmassi S, Keshishi an A. Ventral herniorrhaphy: 
experience with two different bio synthetic mesh materials, Surgisis and Alloderm. 
Hernia. 2006;10 (5):419-425. Epub 2006 Aug 22. 
 
34. Franklin M, Russ ek K.  Use of porcine small intestine  submu cosa as a prosthetic material 
for laparoscopic hernia repair in infected and pot entially contaminated fields: lon g-term 
follow-up assessment. Surg Endosc 2011;25 (5):1693-1694.  
 
35. Holton  LH 3rd, Kim D, Silv erman RP, Rod riguez ED, Singh N, Goldberg NH. Human 
acellular dermal matrix for repair of abdomin al wall defects: review of clinical 
experience and experimental data. J Long Term Eff Med Implants 2005;1 5(5):547-558. 
 
36. Shah BC, Tiwari MM, Goede MR, Eichler MJ, Hollins RR, M cBride CL, Thompson JS, 
Oleynikov D. Not all biolo gics are equal! Hernia 2011;15 (2):165-171. Epub 2010 Dec 
28. 
37. Franklin ME  Jr, Gonzalez JJ Jr, Glass JL, Manjarrez A. Laparoscopic ventral and 
incision al hernia repair: an 11-year experience. Hernia 2004;8 (1):23-27. Epub 2003 S ep 
20. 
 
38. Diaz JJ Jr, Guy J, Berkes MB, Guillamond egui O, Miller RS. Acellular dermal allograft 
for ventral hernia repair in the  compromis ed surgical field. Am Su rg 2006 ;72:1181 -1187.  
CON FIDENTIAL Page 28 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
39. Diaz JJ Jr, Conqu est AM, Ferzoco SJ, Vargo D, Miller P, Wu YC, Donahue R. Multi - 
institution al experience using human acellular dermal matrix for ventral hernia repair in a 
compromis ed surgical field.  Arch Surg 2009;144 (3):209-215. 
 
40. Pomahac B, Aflaki P. Use of a non-cross-linked porcine dermal scaffold in abdomin al 
wall reconstruction. Am J Surg. 2010 Jan;199 (1):22-27. Epub 2009 M ay 9. 
 
41. Jin J, Rosen MJ, Blatnik J, McGee MF, Williams CP, M arks J, Pons ky J. Use of acellular 
dermal matrix for compli cated ventral hernia repair: does technique  affect outcomes? J 
Am Coll Su rg 2007;205 (5):654-660. Epub 2007 S ep 14.  
 
42. Kolker AR, Brown DJ, Redstone  JS, Scarpinato VM, Wallack MK. Multil ayer 
reconstruction of  abdomin al wall defects with acellular dermal allograft (AlloDerm) and 
compon ent separation. Ann Pl ast Su rg 2005;55 (1):36-41; dis cussion 41 -2. 
 
43. Candage R, Jones K, Luchette FA, Sinacore JM, Vandevender D, Reed RL 2nd. Use of 
human acellular dermal matrix for hernia repair: friend or  foe? Surgery 2008;144 (4):703- 
9; dis cussion 709 -711. Epub 2008 Aug 29. 
 
44. CDC Su rgical Site  Infection (SSI) Event Protocol 
http:// www .cdc.gov/nhs n/pdfs/pscmanual/9ps cssicurrent.pdf  
 
45. Patton JH Jr, Berry S, Kralovich KA. Use of human acellular dermal matrix in compl ex 
and contaminated abdomin al wall reconstructions.  Am J Surg 2007;193:3 60-363. 
 
46. Helton WS, Fisichella PM, Berger R, Horgan S, Espat NJ, Abcarian H. Short-term 
outcomes with sm all int estinal submu cosa for ventral abdomin al hernia. Arch Surg 
2005;140:549 -560. 
 
47. Maurice SM, Sk eete DA.  Use of human acellular dermal matrix for abdominal wall 
reconstructions.  Am J Surg 2009;197 (1):35-42. 
 
48. Data on file at Davol Inc. 
 
49. Mangram AJ, Horan TC, Pearson ML, Silv er LC, Jarvis WR.  Guideline for Prevention 
of Surgical Site  Infection.  Infection Cont rol and Hospit al Epidemiolo gy. 1999;20 (4). 
 
50. Novits ky YW, Elliott HL, Orenstein SB, Ros en MJ.  Transversus abdominis mus cle 
release: a novel approach to post erior compon ent separation du ring compl ex abdomin al 
wall reconstruction. Am J Surg. 2012;204 (5):709-16. 
 
51. Specifications M anual for National Hospit al Inpatient Quality Measures.  Version 4.4 a. 
Surgical Care Improvement Project (SCIP). 
CON FIDENTIAL Page 29 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
52. Routine  Cultu re Guidelines Adapted From: SP ECIMEN COLLECTION:  GUIDELINES 
FOR BEST PRACTICES. Center for Health Hazards Preparedness. University of 
Louisvill e. School of  Public  Health and Information Sciences. June 2007.  
 
 
53. Dindo D, Demartines N, Clavien PA. Classification of  Surgical Com plications: A  New 
Propos al with Evaluation in a  Coho rt of 6336 P atients and R esults of  a Survey. Annals of 
Surgery. 2004 Aug; 240 (2):205-13. 
CON FIDENTIAL Page 30 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
18. APPENDICES 
CON FIDENTIAL Page 31 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
18.1. Principal Inv estigator Information 
 
Robert Martindale, MD  
Oregon Health and Science University 
3303 SW  Bond Ave 6th FL  
Portland, OR 97239  
(503) 494-4373  
martindr@ohsu. edu 
CON FIDENTIAL Page 32 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
18.2. Routine Culture [56] 
 
 
BASIC GUIDELINES FOR COLLE CTION  
 
 
 
1. Collect the material from the site in which the  etiologic agent will most lik ely be found. 
 
 
2. Obtain cultures prior to administ ration of  antibiot ics whenever possibl e. 
 
 
3. Collect adequate volume  of material. Inadequate amounts  of specimen may yield false 
negative results.  
 
 
4. Collect specimen in a manner that minimi zes or elimin ates contamination from indig enous 
flora as possible  to ensure that the sample  will be  repre sentative of the infected site. 
 
 
5. Use appropriate collection d evices, transport media, and st erile, leak proof containers. 
 
 
6. Use sterile equipm ent and aseptic technique  to collect specimen to prevent introduction of 
microorganisms du ring invasive procedures. 
 
 
7. Clearly label the specimen including specific information regarding site of collection (e.g., 
blood  obtained via blue lumen of right subclavia central catheter) and compl ete the 
ordering process. 
 
 
8. Identify  the  specimen  source  and/or  specific  site  correctly  so  that  proper  processing 
methods and culture media will be  selected by the laboratory personn el. 
 
 
9. Deliver the specimen prompt ly to the laboratory.  Delay in transpo rt may compromise  the 
specimen. 
 
 
SUBCUTANEOUS AND SKIN SPECIMEN: 
 
 
 
A. Superficial Wound (bacterial) 
1. Syringe aspiration is p referable to swab collection. 
 
 
2. Disinfect the surface of the wound with 70%  alcohol followed by povido ne-iodine  or 
povidon e-iodine  alone.  Allow the skin disin fectant to d ry prior to collection the 
specimen.  R emove  iodine with alcohol after procedure to prevent irritation. 
CON FIDENTIAL Page 33 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
3. Using a 3 – 5 ml syringe with a small gauge needle, a physician will aspirate the deepest 
portion of  the lesion.  If a vesicle is present, collect both fluid and cells from the  base of 
the lesion.  
 
 
4. If the initial aspiration fails to obt ain material, inject sterile, preservative-free saline 
subcutaneously then repeat aspiration if  necessary. 
 
 
5. If no m aterial is obt ained, rinse needle and syringe with broth by drawing the culture 
medium th rough the  needle into the  syringe. 
 
 
WOUND S, ASPIRATES, AND TISS UE SPECIMEN: 
 
 
 
A. Deep Wounds or  Abscesses: 
 
 
1. Disinfect the surface with 70%  alcohol and a povidone-iodine  solution.  R emove  iodine 
with alcohol after procedure to prevent irritation. 
 
2. Aspirate the deepest part of the lesion, avoiding contamination by the wound surface.  If 
collection is done  at surgery, a portion of  the abscess wall should also be  sent for culture. 
 
 
B. Punch Biopsy: 
 
 
1. Disinfect the skin su rface with 70%  alcohol and then with a povidon e-iodine solution.  
Remove  iodine  with alcohol to p revent irritation. 
 
2. Collect 3 – 4 mm s ample  with a dermal pun ch. 
 
3. Submit for culture in a sterile container without formalin. 
 
4. Place specimen onto a  sterile gauze pad moist ened with preservative-free saline in order 
to keep the  specimen from drying. 
 
 
 
C. Soft Tissue  Aspirate 
 
 
1. Disinfect the skin su rface with 70%  alcohol and then with a povidon e-iodine solution.  
Remove  tincture of iodine with alcohol to p revent irritation. 
 
 
2. Aspirate the deepest po rtion of  the lesion or  sinus t ract. Be careful to avoid 
contamination by the wound su rface. 
CON FIDENTIAL Page 34 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
18.3. Surgical Site Infection Classification [44] 
 
Surgical Site Infection Criteria 
 
Superficial Incisional  Surgical Site Infections (SSI) 
 
Infection o ccurs within 30 days after the operative procedure (where day 1 = procedure day) 
AND  
involv es only the skin or  subcutaneous tissue  of the incision 
AND  
at least one of the following: 
A. Purulent drainage from the  superficial incision or  subcutaneous tissu e. 
B. Organisms isol ated from an aseptically obtained culture of fluid or  tissue  from the 
superficial incision.  
C. Superficial incision th at is d eliberately opened by a surgeon, attending physician or other 
designee and is culture positive  or not cultured 
AND  
Patient has at least one  of the following signs or  symptoms: p ain or tenderness; lo calized 
swelling; erythema; or heat. A culture negative finding does not m eet this criterion. 
D. Diagnosis of  a superficial incision al SSI  by the surgeon or  attending physician or other 
designee. 
 
COMMENT : There are two specific types of superficial incision al SSIs: 
1. Superficial Incision al Primary (SIP) –a superficial incision al SSI  that is id entified in the 
primary incision in a  patient that has had an operation with one  or more incisions (e.g., C - 
section in cision or  chest incision for CBGB) 
2. Superficial Incision al Secondary (SIS) – a superficial incision al SSI that is id entified in the 
secondary incision in a  patient that has had an operation with mo re than one incision (e.g., 
donor  site incision for CBGB) 
 
The following do not q ualify as criteria for meeting the definition of  superficial SSI: 
• Diagnosis/t reatment of cellulitis (redness/warmth/s welling), by itself, does not m eet 
criterion d for superficial incision al SSI.  An incision th at is d raining  or culture (+) is not 
consid ered a cellulitis.  
• A stitch abscess alone (minim al inflammation and dis charge confined to the  points of  
suture penetration). 
 
Deep Incisional SSI  
Infection o ccurs within 90 days after the operative procedure (for herniorrhaphy)(where day 1 
= procedure day) 
AND  
involv es deep soft tissu es of the incision (e.g., fascia and mus cle layers) 
AND  
patient has at least one of the following: 
a. Purulent drainage from the  deep incision.  
CON FIDENTIAL Page 35 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
b. A deep incision spont aneously dehisces or is deliberately opened or aspirated by a 
surgeon, attending physician or other designee and is culture positive  or not cultured 
AND  
patient has at least one of the following signs or  symptoms:  fever (>38°C ), localized 
pain or tenderness.  A  culture negative finding  does not m eet this criterion. 
c. An abscess or other evidence of infection involving  the deep incision th at is detected 
on gross anatomical or histopatholo gic exam, or  imaging test. 
 
COMMENT S: There are two specific types of deep incision al SSIs: 
 
1. Deep Incision al Primary (DIP) –a deep incisional SSI that is id entified in a  primary incision 
in a patient that has had an operation with one  or more incisions (e.g., C-section in cision or 
chest incision for CBGB) 
2. Deep Incision al Secondary (DIS) – a deep incisional SSI  that is identified in the  secondary 
incision in a  patient that has had an operation with mo re than one  incision  (e.g., donor  site 
incision for CBGB) 
 
Organ/Spa ce SSI 
Must m eet the following criteria: 
Infection o ccurs within 90 days after the operative procedure (for herniorrhaphy)(where day 1 
= procedure day) 
AND  
infection involv es any part of the body deeper than the  fascial/muscle layers, that is op ened or 
manipul ated during the operative procedure 
AND  
patient has at least one of the following: 
a. purulent drainage from a drain that is pl aced into the  organ/space (e.g., closed suction 
drainage system, op en drain, T-tube drain, CT  guided drainage) 
b. organisms isol ated from an aseptically-obtained culture of fluid or  tissue in the 
organ/space 
c. an abscess or other evidence of infection involving  the organ/space that is detected on 
gross anatomical or histopatholo gic exam, or  imaging test 
AND  
meets at least one of the organ/space infection site  “intraabdomin al” criteria: 
1. Patient has organisms cultured from abscess and/or purulent material from 
intraabdomin al space. 
2. Patient has abscess or other evidence of intraabdominal infection on g ross anatomic  or 
histop atholo gic exam. 
3. Patient has at least two of the following signs or  symptoms: fever (>38.0°C±), nausea*, 
vomitin g*, abdomin al pain*, or  jaundice* 
And at  least one of the following: 
a. organisms s een on culture or Gram stain of drainage or tissue  obtained during 
invasive procedure or from an aseptically-placed drain (e.g., closed suction 
drainage system, op en drain, T-tube drain, CT  guided drainage) 
CON FIDENTIAL Page 36 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
b. organisms cultured from blood and im aging test evidence suggestive  of infection 
(e.g., ultrasound, CT  scan, M RI, radiolabel scans [gallium, t echnetium, etc.] or on 
abdomin al x-ray), which if equivo cal is suppo rted by clinical correlation. 
* With no oth er recognized cause 
± As documented in the  medical record 
CON FIDENTIAL Page 37 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
18.4. Clavien Dindo Classification [57] 
 
Grades Definition  
Grade I Any deviation from the  normal postop erative course without the  need for 
pharmacological treatment or surgical, endos copic and radiological 
interventions  
Allowed therapeutic regimens are: drugs as anti-emetics, antipyretics, 
analgetics, diu retics and electrolytes and physiotherapy. This grade also 
includes wound in fections opened at the bedside. 
Grade II Requiring pharmacological treatment with drugs other than such allowed for 
grade I compli cations.  
Blood t ransfusions and total parenteral nutrition are also in cluded. 
Grade III Requiring surgical, endoscopic or radiological intervention  
- IIIa Intervention not und er general anesthesia 
- IIIb Intervention und er general anesthesia 
Grade IV Life-threatening compli cation (including  CNS complications )* requiring 
IC/ICU-management 
- IVa single organ dysfunction (including  dialysis) 
- IVb Multi -organ dysfunction 
Grea de V Death of a patient 
Suffix "d" If the patients su ffers from a compli cation at the time of discharge, the 
suffix  "d" (for 'disability') is added to the  respective grade of compli cation. 
This label indi cates the need for a follow-up to fully evaluate the 
compli cation. 
 
 
 
 
*brain hemorrhage, ischemic stroke, sub -arrachnoidal bleeding, but excluding  transient ischemic 
attacks (TIA);IC: Intermediate care; ICU: Intensive care unit. 
CON FIDENTIAL Page 38 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 
18.5. Instructions for Use 
CON FIDENTIAL Page 39 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 

CON FIDENTIAL Page 40 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 

CON FIDENTIAL Page 41 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 

CON FIDENTIAL Page 42 of 42 Davol Inc. 
XenMatrix™ AB Surgical Graft Protocol Version 3.0 
August  07, 2018  
 
  
 
 
 
